Rubric Capital Management (New York)’s Arbutus Biopharma ABUS Stock Holding History

Rubric Capital Management (New York)’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.2M	Buy	7,532,937 +906,548	+14%	+$3.98M	0.33%	61
2026 Q1	$29.8M	Buy	6,626,389 +5,051,013	+321%	+$22.1M	0.32%	57
2025 Q4	$7.58M	Hold	1,575,376	–	–	0.09%	70
2025 Q3	$7.15M	Hold	1,575,376	–	–	0.08%	66
2025 Q2	$4.87M	Sell	1,575,376 -105,714	-6%	-$351K	0.07%	60
2025 Q1	$5.87M	Hold	1,681,090	–	–	0.11%	56
2024 Q4	$5.5M	Hold	1,681,090	–	–	0.07%	60
2024 Q3	$6.47M	Hold	1,681,090	–	–	0.11%	55
2024 Q2	$5.19M	Buy	+1,681,090	New	+$5.04M	0.14%	61
2023 Q3	–	Sell	-3,395,855	Closed	-$7.81M	–	62
2023 Q2	$7.81M	Sell	3,395,855 -799,217	-19%	-$2.08M	0.33%	51
2023 Q1	$12.7M	Buy	4,195,072 +728,791	+21%	+$2.06M	0.33%	51
2022 Q4	$8.08M	Buy	+3,466,281	New	+$8.29M	0.35%	61

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rubric Capital Management (New York)'s ABUS Position: Q2 2026 in Review

Rubric Capital Management (New York) increased its Arbutus Biopharma (ABUS) stake by 14% in Q2 2026, buying an estimated $3.98M and bringing the position to 7,532,937 shares worth $36.2M. The position accounts for 0.33% of the portfolio, ranked #61.

Rubric Capital Management (New York) first reported a position in ABUS in Q4 2022 and has held it in 12 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Rubric Capital Management (New York) held 7,532,937 shares of Arbutus Biopharma worth $36.2M as of Q2 2026.
Rubric Capital Management (New York) bought 906,548 Arbutus Biopharma shares in Q2 2026, an estimated $3.98M.
Arbutus Biopharma made up 0.33% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #61 holding.
Rubric Capital Management (New York) first reported a position in Arbutus Biopharma in Q4 2022 and has held it in 12 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.